Antikonvülzan İlaç Zehirlenmeleri

Authors

Semih Eriten

Synopsis

Antikonvülzan ilaçlar epilepsi, nöropatik ağrı, migren ve psikiyatrik hastalıkların tedavisinde nöronal uyarımı bastırmak amacıyla kullanılan ve dar terapötik aralıkları nedeniyle zehirlenme riski taşıyan ajanlardır. Başarılı bir ilaç tedavisi için hasta uyumu, emilim, metabolizma ve cinsiyet veya yaşa bağlı fizyolojik farklılıklar belirleyici olup, karbamazepin, fenitoin, fenobarbital ve valproik asit gibi klasik antikonvülzanların rutin terapötik ilaç izlemi (Tİİ) büyük önem taşımaktadır. Fenobarbital hariç klasik antikonvülzanlar serum proteinlerine yüksek oranda bağlandığından; üremi, karaciğer rahatsızlığı, hipoalbüminemi, gebelik ve yoğun bakım süreçlerinde serbest (aktif) ilaç düzeylerinin doğrudan ölçülmesi toksisiteyi ve klinik uyumsuzlukları önlemek açısından zorunludur. Laboratuvarlarda otomasyon ve pratiklik sağlayan immünokimyasal yöntemler sıklıkla tercih edilmekle birlikte, karbamazepinin aktif metaboliti olan karbamazepin 10,11-epoksit gibi bileşiklerle ortaya çıkan çapraz reaksiyonlar ve interferanslar hatalı sonuçlara yol açabilmekte, bu durumlarda kromatografik teknikler daha hassas çözümler sunmaktadır. Yeni nesil antikonvülzanlar ise daha geniş terapötik aralıkları sebebiyle genel olarak rutin izleme daha az ihtiyaç duyar. Antikonvülzan doz aşımlarında EKG değişiklikleri, QRS ve QT uzaması, aritmiler ile hipotansiyon gibi ciddi kardiyovasküler toksisite tabloları gözlenebilir; zehirlenme tedavisinde oral veya nazogastrik yolla aktif kömür uygulaması yapılırken, QRS aralığının 100 milisaniyeyi aşması halinde sodyum bikarbonat tedavisi uygulanmaktadır.

Anticonvulsant drugs are agents used to suppress neuronal excitation in the treatment of epilepsy, neuropathic pain, migraine, and psychiatric disorders, carrying a risk of poisoning due to their narrow therapeutic index. Patient compliance, absorption, metabolism, and physiological differences related to age or gender are key factors for successful therapy, making routine therapeutic drug monitoring (TDM) crucial for classic anticonvulsants such as carbamazepine, phenytoin, phenobarbital, and valproic acid. Since classic anticonvulsants—except phenobarbital—are highly bound to serum proteins, directly measuring free (active) drug levels is essential to prevent toxicity and clinical complications in conditions like uremia, liver disease, hypoalbuminemia, pregnancy, and intensive care. Although immunochemical methods providing automation and convenience are commonly preferred in laboratories, cross-reactions and interferences caused by compounds like carbamazepine 10,11-epoxide, the active metabolite of carbamazepine, can lead to inaccurate results, where chromatographic techniques offer more sensitive solutions. In contrast, new-generation anticonvulsants generally require less routine monitoring due to their wider therapeutic index. In anticonvulsant overdoses, severe cardiovascular toxicity such as ECG changes, QRS and QT prolongation, arrhythmias, and hypotension may occur; overdose management includes oral or nasogastric activated charcoal administration, alongside sodium bicarbonate therapy if the QRS duration exceeds 100 milliseconds.

References

Gray LA. Anticonvulsant toxicity. Medicine. 2020; 48(3): 192-193.

McMillin GA, Jueiike JM, Johnson M et al. Discordant carbamazepine values between two immunoassays: carbamazepine values determined by ADVIA Centaur correlate better with those determined by PETINIA assay. J Clin Lab Anal 2011; 25: 212-216.

McMillin GA, Juenke JM, Tso G et al. Estimation of carbamazepine and carbamazepine 10, 11-epoxide concentrations in plasma using mathematical equa- tions generated with two carbamazepine immunoassays. Am J Clin Pathol 2010; 133; 728-736.

Parant F, Moulsma M, Gagnieu MC et al. Hydroxyzine and metabolites as a source of interference in carbamazepine particle-enhanced turbidimetric inhibition immunoassay (PETINIA). Ther Ding Monit 2005; 27: 457-462.

Klotz U. The role of pharmacogenomics in the metabolism of antiepileptic dings: pharmacokinetics and therapeutic implications. Clin Phannacokinet 2007: 46:271-279.

McMillin GA, Jueiike JM, Johnson M et al. Discordant carbamazepine values between two immunoassays: carbamazepine values determined by ADVIA Centaur correlate better with those determined by PETINIA assay. J Clin Lab Anal 2011; 25: 212-216.

Kemper EM, van Khan HJ, Speelman P et al. Severe phenytoin intoxi- cation in patients with hypoalbuminemia [in Dutch], Ned Tjdschr Geneeskd 2007; 151: 138-141.

Wolf GK. McClain CD, Zurakoski D et al. Total phenytoin concentra- tions do not accurately predict free phenytoin concentrations in critically ill children. Pediatr Crit Care Med 2006; 7: 434-439.

Dasgrupta A. (2018).Toksi̇koloji̇ ve terapöti̇k ilaç izlemi̇nde hatalı sonuçların değerlendi̇rilmesi. Ankara: Pegem Yayınevi.

Datta P, Dasgupta A. Cross-reactivity of fosphenytoin in four phenytoin immunoas- says. Clin Chem 1998; 44: 696-697.

Frank EL, Schwarz EL, Juenke J et al. Performance characteristics of fom immunoassays for antiepileptic drugs on the IMMULITE 2000 automated analyzer. Am J Clin Pathol 2002; 118: 124-131.

Parant F, Moulsma M, Gagnieu MC et al. Hydroxyzine and metabolites as a source of interference in carbamazepine particle-enhanced turbidimetric inhibition immunoassay (PETINIA). Ther Ding Monit 2005; 27: 457-462.

Datta P. Scurlock D. Dasgupta A. Analytic performance evaluation of a new turbidimetric immunoassay for phenytoin on the ADVIA 1650 analyzer: effect of phenytoin metabolite and analogue. Tlier Drug Monit 2005; 27: 305-308.

Datta P, Dasgupta A. Cross-reactivity of fosphenytoin in four phenytoin immunoas- says. Clin Chem 1998; 44: 696-697.

Frank EL, Schwarz EL, Juenke J et al. Performance characteristics of fom immunoassays for antiepileptic drugs on the IMMULITE 2000 automated analyzer. Am J Clin Pathol 2002; 118: 124-131.

Pippenger CE, Gillen HW. Gas chromatographic analysis for anticonvulsant drugs in biologic fluids. Clin Chem 1969; 15: 582-590.

Rainey PM. Rogers KE, Roberts WL. Metabolite and matrix interference in phe- nytoin immunoassays. ClinChem 1996:42: 1645-1653.

Matzke GR. Sawchuk RJ. Elevated seimn phenytoin concentrations in uremic patient measured by enzyme multiplied immunoassay. Drug Intell Clin Phann 1981;15: 386-388.

Tutor-Crespo MJ, Hermida J, Tutor JC. Phenytoin immunoassay measurements in serum from patients with renal insufficiency: comparison with high-performance liquid chromatography. J Clin Lab Anal 2007; 21: 119-123.

Tutor-Crespo MJ. Hennida J, Tutor JC. Relative proportions of serum carbamaze- pine and its pharmacologically active 10, 11-epoxide derivative: effect of polytherapy and renal insufficiency. Ups J Med Sci 2008; 113: 171-180.

Parant F, Moulsma M, Gagnieu MC, Lardet G. Hydroxyzine and metabolites as a source of interference in carbamazepine particle-enhanced turbidimetric inhibition immunoassay (PETINIA). Ther Ding Monit 2005; 27: 457-462.

Dasgupta A, Tso G, Johnson M, Chow L. Hydroxyzine and cetirizine interfere with the PETINIA carbamazepine assay but not with the ADVIA CENTEUR carba- mazepine assay. Ther Drug Monit 2010; 32: 112-115.

Ainmann H, Vinet B. Accuracy, precision, and interferences of three modified EMIT procedures for determining serum phénobarbital, urine morphine, and urine cocaine metabolite with a Cobas-Fara. Clin Chem 1991; 37: 2139-2141.

Nordt SP. Butalbital cross-reactivity to an EMIT assay for phénobarbital. Ami Phannacother 1997;31:254-255.

Meinardi H. Vander Kleijn E, Meijer JWA. Absoiption and distribution of antiepileptic drugs. Epilepsia 1982; 23: 23-26.

Yuan R, Venitz J. Effect of chronic renal failure on the disposition of highly hepati- cally metabolized drugs. Int J Clin Pharmacol 2000; 38: 245-253.

Gulyassy PF, Jarrard E, Stanfel L. Roles of hippurate and indoxyl sulfate in the unpaired ligand binding by azotemic plasma. Adv Exp Med Biol 1987; 223: 55-58.

Ghuman J, Zmiszain P, Petitpas I et al. Structural basis of drug- binding specificity of human serum albumin. J Mol Biol 2005; 353: 38-52.

Zielmaim S, Mielck F, Kahl R et al. A rational basis for the measure- ment of free phenytoin concentration in critically ill trauma patients. Tlier Dnig Monit 1994; 16:139-144.

Gidal BE, Collins DM, Beinlich BR. Apparent valproic acid neurotoxicity in a hypoalbuminémie patient. Ami Phannacother 1993; 27; 32-35.

Haroldson JA, Kramer LE, Wolff DL et al.Elevated free fr actions of valproic acid in a heart transplant patient with hypoalbuminemia. Ami Phannacother 2000: 34: 183— 187.

de Matt M, van Leeuwen HJ, Edelbroek PM. High unbound fraction of valproic acid in a hypoalbuminémie critically ill patient on renal replacement therapy. Ami Phannacother 2011; 45: el8.

Pennell PB. Antiepileptic ding pharmacokinetics during pregnancy and lactation. Neurology 2003: 61 (Suppl 2): S35-S42.

Dasgupta A, Dennen DA, Dean R et al. Displacement of phenytoin from serum protein carriers by antibiotics: studies with ceftriaxone, nafcillin and sulfamethoxazole. Clin Chem 1991; 37: 98-100.

Bates DE. Herman RJ. Carbamazepine toxicity induced by lopinavir/ritonavir and nelfinavir. Ami Pharmacother 2006; 40: 1190-1194.

Dökmeci İ. (2001). Toksikoloji. 3. Baskı. İstanbul: Nobel Tıp Kitabevi

Curry SC. Medical toxicology. Critical Care Clinics. 1997; (4).

Downloads

Published

April 6, 2021

License

License